资讯

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst
Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial. Click here to find out why I rate ...
INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting ...
INmune Bio's XPro1595 targets soluble TNF for Alzheimer's. Phase 2 results could reshape inflammatory disease treatment.